Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07606625
PHASE4

Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment

Sponsor: University of California, Berkeley

View on ClinicalTrials.gov

Summary

The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).

Official title: The Impact of Varenicline Nasal Spray 0.03mg Dry Eye Treatment on Ocular Surface Health, Tear Film Stability, and Ocular Discomfort

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

65

Start Date

2026-03-06

Completion Date

2026-12-31

Last Updated

2026-05-27

Healthy Volunteers

No

Interventions

DRUG

Varenicline 0.03Mg/Spray Nasal Soln

After meeting eligibility criteria and signing informed consent, participants will be dispensed a 3-month supply of varenicline 0.03mg/spray nasal solution. Participants will take the nasal spray home and spray once in each nostril twice daily for 3 months

Locations (1)

U.C. Berkeley Clinical Research Center

Berkeley, California, United States